ReNerve launches Empliq range targeting US dermal and amniotic tissue market

• ReNerve launches new Empliq product range in US tapping into lucrative dermal and amniotic tissue market
• Empliq range made from natural bioactive components and designed to complement NerveAlign range
• Includes four products for soft tissue repair, reinforcement, or replacement

Special Report: Developer of products for peripheral nerve repair ReNerve has launched its Empliq range in the US after recently completing first sales of the human tissue products.

Developed in conjunction with US-based Berkeley Biologics, the product range is complementary to the existing ReNerve (ASX:RNV) product portfolio.

The Empliq product range has uses in medical procedures that ReNerve seeks to address with its current and future NervAlign range of nerve repair and nerve replacement products.

The range will be an extension of its current sales activities, using the same sales network and targeting the same surgeon and hospital customers.

Natural barrier for wound care

The range includes four products designed for soft tissue repair, reinforcement or replacement applications.

Made from natural bioactive components including collagen, elastic and glycosaminoglycans they are designed to mimic the properties of the human dermia.

ReNerve said the amniotic and placental allografts provide a supportive natural barrier for wound closure and would be particularly useful in chronic wound care.

The companies said the products enable rapid, non-pathologic healing and tissue remodelling while providing a reservoir of growth factors and cytokines to help jump-start the healing process.

The allografts are flexible, pliable, and easy to apply, with a high sterility assurance level and room temperature storage.

They are associated with a low inflammatory response, making them suitable for a wide range of clinical applications.

Tapping into lucrative market

The dermal and amniotic tissue market is estimated to reach more than $1.5 billion in 2026 and more than $3bn by 2032.

RNV plans market launch activities at the upcoming American Society for Surgery of the Hand conference in Vancouver in the first half of October.

The initial sale of the EmpliqDermal deep-layer matrix product comes ahead of the planned launch of the amniotic and placental allograft products in Q3 CY25.

“The launch of the Empliq range is a key step in our strategy to provide a broad suite of products to surgeons, whilst it complements our existing nerve repair product range,” ReNerve CEO Dr Julian Chick said.

“We’ve developed and completed all the branding and marketing materials for Empliq, and the products are now available to our sales teams across the US.”

This article was developed in collaboration with ReNerve, a Stockhead advertiser at the time of publishing.

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.